MedTrace Logo

Effects Of Income Supplements On 30-Day Readmissions For Vulnerable Older Adults

NCT05807750 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 8

Last updated 2024-06-03

No results posted yet for this study

Summary

Unplanned 30-day hospital readmissions are an critical healthcare quality metric, with meaningful effects on patients and health systems operations. Interventions to reduce unplanned readmissions have primarily operated within a healthcare-centric frame, with enhancements to either pre- or post-discharge care planning, medication reconciliation, or visit frequency. Associations of 30-day readmission rates with poverty status and other social factors, however, suggest that attending to unmet social needs may yield added benefits to models focused on healthcare delivery. The purpose of the present trial is to provide evidence regarding the effects on 30-day readmissions of providing a one-time post-discharge income supplement to socially vulnerable older adults with medical complexity participating in an enhanced care coordination program.

Conditions

  • Patient Readmission

Interventions

OTHER

Post-discharge income supplement

$300 income supplement

OTHER

Enhanced care planning

Enhanced care planning provided by a nurse care manager

Sponsors & Collaborators

  • National Institute on Aging (NIA)

    collaborator NIH

  • University of Southern California

    collaborator OTHER

  • AltaMed Health Services Corporation

    lead OTHER

Principal Investigators

  • Rajan A Sonik, PhD, JD, MPH · Brandeis University

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
55 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-06-21
Primary Completion
2024-04-22
Completion
2024-04-22

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05807750 on ClinicalTrials.gov